18F-FDG PET/CT用于极早期疗效评估预测厄洛替尼治疗非小细胞肺癌患者的CT疗效:评估方法比较
研究在50例厄洛替尼治疗的非小细胞肺癌患者中,于治疗前及治疗7-10天后行18F-FDG PET/CT,比较定性及多种半定量方法对治疗9-11周后CT疗效的预测价值。结果显示,按PERCIST标准勾画的TLG与靶病灶最长径之和变化相关性最强(R=0.564,P<0.001),预测CT进展的AUC最高为0.92(95%CI 0.84-1.00);TLG(PERCIST)采用25%变化界值对部分代谢缓解和进展性代谢病预测CT疗效类别的κ值为0.53(95%CI 0.31-0.75),可识别41%的后续CT进展患者且无假阳性。结论认为TLG(PERCIST)是预测后续CT疗效的最佳指标,优于SULpeak和SULmax。
要点
- TLG(PERCIST)与靶病灶最长径之和变化相关性最强(R=0.564,P<0.001),优于SULmax(R=0.298,P=0.039)和SULpeak(R=0.402,P=0.005)。
- TLG(PERCIST)预测CT进展的AUC为0.92(95%CI 0.84-1.00),定性视觉评估正确分类50%(κ=0.47,95%CI 0.24-0.70)。
- TLG(PERCIST)采用25%变化界值可识别41%的后续CT进展患者且无假阳性,κ值为0.53(95%CI 0.31-0.75)。
核心结论
- TLG(PERCIST)是预测后续CT疗效的最佳指标,优于SULpeak和SULmax。
- 治疗1-2周后采用TLG(PERCIST)25%界值可安全识别41%不会从厄洛替尼获益的患者,并在此时间点停止治疗。
研究设计与样本
- 研究纳入50例非小细胞肺癌患者,在厄洛替尼治疗前及治疗7-10天后行18F-FDG PET/CT,采用定性及半定量方法(SUV百分比变化、SULpeak、SULmax、TLG)评估。
- 将PET参数及对应疗效类别与厄洛替尼治疗9-11周后CT扫描的靶病灶最长径之和百分比变化及疗效类别进行比较,使用受试者工作特征分析、线性回归和二次加权κ分析。
主要发现
- TLG(PERCIST)与靶病灶最长径之和变化相关性最强(R=0.564,P<0.001),优于SULmax(R=0.298,P=0.039)和SULpeak(R=0.402,P=0.005)。
- 预测CT进展的受试者工作特征分析显示曲线下面积在0.79至0.92之间,TLG(PERCIST)的曲线下面积最高为0.92(95%CI 0.84-1.00)。
- TLG(PERCIST)采用25%变化界值同时用于部分代谢缓解和进展性代谢病时,预测CT疗效类别的κ值为0.53(95%CI 0.31-0.75),可识别41%的后续CT进展患者且无假阳性。
- 定性视觉评估正确分类50%,κ值为0.47(95%CI 0.24-0.70)。
关键数值与推荐
- TLG(PERCIST)采用25%变化界值作为部分代谢缓解和进展性代谢病的判断标准。
- TLG(PERCIST)预测CT进展的曲线下面积为0.92(95%CI 0.84-1.00)。
- TLG(PERCIST)25%界值预测CT疗效类别的κ值为0.53(95%CI 0.31-0.75)。
临床怎么用
- 作者认为,治疗1-2周后采用TLG(PERCIST)25%界值可安全识别41%不会从厄洛替尼获益的患者,并在此时间点停止治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The purpose of this study was to determine which method for early response evaluation with 18F-FDG PET/CT performed most optimally for the prediction of response on a later CT scan in erlotinib-treated non-small cell lung cancer patients. Methods:18F-FDG PET/CT scans were obtained before and after 7-10 d of erlotinib treatment in 50 non-small cell lung cancer patients. The scans were evaluated using a qualitative approach and various semiquantitative methods including percentage change in SUVs, lean body mass-corrected (SUL) SULpeak, SULmax, and total lesion glycolysis (TLG). The PET parameters and their corresponding response categories were compared with the percentage change in the sum of the longest diameter in target lesions and the resulting response categories from a CT scan obtained after 9-11 wk of erlotinib treatment using receiver-operating-characteristic analysis, linear regression, and quadratic-weighted κ. Results: TLG delineation according to the PERCIST showed the strongest correlation to sum of the longest diameter (R = 0.564, P < 0.001), compared with SULmax (R = 0.298, P = 0.039) and SULpeak (R = 0.402, P = 0.005). For predicting progression on CT, receiver-operating-characteristic analysis showed area under the curves between 0.79 and 0.92, with the highest area under the curve of 0.92 (95% confidence interval [CI], 0.84-1.00) found for TLG (PERCIST). Furthermore, the use of a cutoff of 25% change in TLG (PERCIST) for both partial metabolic response and progressive metabolic disease, which is the best predictor of the CT response categories, showed a κ-value of 0.53 (95% CI, 0.31-0.75). This method identifies 41% of the later progressive diseases on CT, with no false-positives. Visual evaluation correctly categorized 50%, with a κ-value of 0.47 (95% CI, 0.24-0.70). Conclusion: TLG (PERCIST) was the optimal predictor of response on later CT scans, outperforming both SULpeak and SULmax The use of TLG (PERCIST) with a 25% cutoff after 1-2 wk of treatment allows us to safely identify 41% of the patients who will not benefit from erlotinib and stop the treatment at this time.
引用
- Fledelius J, Winther-Larsen A, Khalil AA, et al. 18F-FDG PET/CT for Very Early Response Evaluation Predicts CT Response in Erlotinib-Treated Non-Small Cell Lung Cancer Patients: A Comparison of Assessment Methods. J Nucl Med. 2017. PMID: 28490472. doi:10.2967/jnumed.117.193003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。